Ratio of baseline erythropoietin (EPO) level and corrected reticulocyte count as an indicator for a favourable response to recombinant human erythropoietin (rhEPO) therapy in anaemic cancer patients

Journal of Clinical Laboratory Analysis

Volumn 15, Issue 5, 2001, Pages 260-266

  Charuruks, Navapun ^a,b   Voravud, Narin ^a   Limpanasithikul, Wacharee ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

Author keywords

Anaemia in malignancy; Baseline EPO level; Corrected reticulocyte count; Erythropoietin therapy

Indexed keywords

ANTINEOPLASTIC AGENT; ERYTHROPOIETIN; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE COUNT; FEMALE; HUMAN; MALE; RETICULOCYTE COUNT; TREATMENT PLANNING;

ADULT; AGED; ANEMIA; ERYTHROCYTE INDICES; ERYTHROCYTES; ERYTHROPOIETIN; FEMALE; HEMATOCRIT; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PROGNOSIS; RECOMBINANT PROTEINS; RETICULOCYTE COUNT;

EID: 0034821780     PISSN: 08878013     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcla.1038     Document Type: Article

References (23)

1. Cancer-related anaemia: Its causes and characteristics
2. Anaemia of chronic disease: Spectrum of associated diseases in a series of unselected hospitalized patients
3. Pathogenesis and treatment of the anaemia of chronic diseases
4. The haemetological stress syndrome
5. Anaemia in rheumatoid arthritis: Pathogenesis, diagnosis and treatment
6. Decreased erythropoietin response in patients with the anaemia of cancer
7. Recombinant human erythropoietin and the anaemia of cancer
8. The anaemia of chronic disease
9. Serum immunoreactive erythropoietin in HIV infected patients
10. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anaemia: Results of double-blind and open-labeled follow-up studies
11. The frequency of red cell transfusion for anaemia in patients receiving chemotherapy. A retrospective cohort study
12. Transmission of disease by blood transfusion
13. Transfusion risks
14. Recombinant human erythro-poietin therapy combination chemotherapy
15. Progress in understanding erythropoiesis
16. Anaemia of malignancy
17. Prediction of response to treatment with human recombinant erythropoietin in myelodysplastic syndromes
18. Prediction of response to erythropoietin treatment in chronic anaemia of cancer
19. Recombinant human erythropoietin in the anaemia associated with multiple myeloma or nonHodgkin lymphoma: Dose finding and identification of predictors of response
20. Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells
21. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin receptor
22. Quantitative assessment of erythropoiesis and functional classification of anaemia based on measurements of serum transferrin receptor and erythropoietin
23. Prediction of response to reombinant human erythropoietin (rHuEpo) in anaemia of malignancy